Advanced Sterility Testing Technologies

Abstract

Sterility testing verifies that pharmaceutical products, biologics, medical devices, and advanced therapies meet the microbiological quality standards required for safe clinical use. The compendial sterility test codified in USP <71>, Ph. Eur. 2.6.1, and JP 4.06 has been the regulatory standard for decades, requiring a 14-day incubation period that creates substantial product release delays and that has demonstrated sensitivity limitations for certain challenging organisms. Advanced sterility testing technologies -- rapid microbial methods using ATP bioluminescence, nucleic acid amplification, flow cytometry, and emerging NGS-based approaches -- have matured to the point where several now have regulatory acceptance for pharmaceutical release testing, with advantages in detection speed, organism range, and automation suitability that the compendial method cannot match. This study presents the Sterility Testing Technology Assessment Framework (STTAF), evaluating five sterility testing approaches -- traditional compendial USP <71>/Ph. Eur. 2.6.1/JP 4.06 method (TCS-CM), ATP bioluminescence-based rapid sterility testing (ATP-RST), nucleic acid amplification technology-based detection (NAT-DT), flow cytometry-based microbial enumeration (FC-ME), and next-generation sequencing-based microbial detection (NGS-MD) -- across four product contexts: pharmaceutical sterile products, biologics and cell therapies, implantable medical devices, and advanced therapy medicinal products with short shelf life. Performance was scored using the Sterility Test Effectiveness Score (STES), a weighted composite of detection sensitivity (0.25), result turnaround time (0.20), organism detection range (0.20), regulatory acceptance (0.20), and operational feasibility (0.15). NAT-based detection achieved the highest STES (0.884) through strong detection sensitivity (0.920) and rapid turnaround (0.940). ATP bioluminescence ranked second (0.872) with the best operational feasibility (0.920). Flow cytometry (0.858) provides quantitative enumeration capability. NGS-based detection (0.841) offers the broadest organism range but faces regulatory precedent gaps. Traditional compendial method (0.831) maintains the highest regulatory acceptance (0.960) but is limited by the 14-day turnaround time that has become operationally limiting for advanced therapy products with short shelf life.